Walleye Capital LLC reduced its stake in Kodiak Sciences Inc. (NASDAQ:KOD – Get Rating) by 95.4% in the second quarter, Holdings Channel.com reports. The fund owned 16,389 shares of the company’s stock after selling 339,704 shares during the period. Walleye Capital LLC’s holdings in Kodiak Sciences were worth $125,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently made changes to their positions in the company. BlackRock Inc. boosted its stake in Kodiak Sciences by 20.5% during the first quarter. BlackRock Inc. now owns 3,435,960 shares of the company’s stock valued at $26,526,000 after buying an additional 584,762 shares during the period. Acadian Asset Management LLC bought a new stake in Kodiak Sciences during the first quarter valued at $3,603,000. Krensavage Asset Management LLC bought a new stake in Kodiak Sciences during the first quarter valued at $3,479,000. Monaco Asset Management SAM boosted its stake in Kodiak Sciences by 518.1% during the second quarter. Monaco Asset Management SAM now owns 464,798 shares of the company’s stock valued at $3,551,000 after buying an additional 389,598 shares during the period. Finally, Graham Capital Management L.P. bought a new stake in Kodiak Sciences during the first quarter valued at $2,282,000. 78.37% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on KOD. Truist Financial lifted their price objective on Kodiak Sciences from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, August 9th. Morgan Stanley dropped their price target on Kodiak Sciences from $12.00 to $9.00 and set an “equal weight” rating for the company in a research note on Monday, November 14th. The Goldman Sachs Group dropped their price target on Kodiak Sciences from $9.00 to $8.00 and set a “neutral” rating for the company in a research note on Thursday, November 10th. Chardan Capital dropped their price target on Kodiak Sciences from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, August 10th. Finally, Capital One Financial initiated coverage on Kodiak Sciences in a research note on Tuesday, November 15th. They set an “overweight” rating and a $24.00 price target for the company. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Kodiak Sciences has a consensus rating of “Hold” and an average price target of $25.11.
Kodiak Sciences Trading Down 0.4 %
Kodiak Sciences Profile
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
- Get a free copy of the StockNews.com research report on Kodiak Sciences (KOD)
- Is GameStop Stock Setting Up for Another Short Squeeze?
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.